Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 33, 2018 - Issue 1
Submit an article Journal homepage
1,112
Views
14
CrossRef citations to date
0
Altmetric
Research Paper

Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies

Mohammed I. El-GamalDepartment of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates; ;Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates; ;Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, Egypt; ORCID Iconhttp://orcid.org/0000-0002-4269-5264View further author information
ORCID Icon &
Chang-Hyun OhCenter for Biomaterials, Korea Institute of Science and Technology, Seoul, Republic of Korea; ;Department of Biomolecular Science, University of Science and Technology, Daejeon, Republic of KoreaCorrespondence[email protected]
View further author information
Pages 1160-1166 | Received 26 Apr 2018, Accepted 18 Jun 2018, Published online: 02 Aug 2018

References

  • Sherr CJ. The fms oncogene. Biochim Biophys Acta 1988;948:225–43.
  • Woolford J, Rothwell V, Rohrschneider L. Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage. Mol Cell Biol 1985;5:3458–66.
  • Kacinski BM, Carter D, Mittal K, et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 1990;137:135–47.
  • Zhu P, Baek SH, Bourk EM, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124:615–29.
  • Morandi A, Barbetti V, Riverso M, et al. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. PLoS One 2011;6:e27450.
  • Swierczak A, Cook A, Lenzo J, et al. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunol Res 2014;2:765–76.
  • Sullivan AR, Pixley FJ. CSF-1R signaling in health and disease: a focus on the mammary gland. J Mammary Gland Biol Neoplasia 2014;19:149–59.
  • El-Gamal MI, Anbar HS, Yoo KH, et al. FMS kinase inhibitors: current status and future prospects. Med Res Rev 2013;33:599–636.
  • El-Gamal MI, Al-Ameen SK, Al-Koumi DM, et al. Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors. J Med Chem 2018;61:5450–466.
  • Genovese MC, Hsia E, Belkowski SM, et al. Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. J Rheumatol 2015;42:1752–61.
  • Li P, He K, Li J, et al. The role of Kupffer cells in hepatic diseases. Mol Immunol 2017;85:222–9.
  • von Tresckow B, Morschhauser F, Ribrag V, et al. An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Clin Cancer Res 2015;21:1843–50.
  • Tresckow BV, Morschhauser F, Ribrag V, et al. A phase 1 study of JNJ-40346527, a colony stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Blood 2013;122:1812.
  • Meegalla SK, Wall MJ, Chen J, et al. Structure-based optimization of a potent class of arylamide FMS inhibitors. Bioorg Med Chem Lett 2008;18:3632–7.
  • Illig CR, Manthey CL, Meegalla SK, et al. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors. Bioorg Med Chem Lett 2013;23:6363–9.
  • El-Gamal MI, Jung M-H, Oh C-H. Discovery of a new potent bisamide FMS kinase inhibitor. Bioorg Med Chem Lett 2010;20:3216–8.
  • El-Gamal MI, Abdel-Maksoud MS, Gamal El-Din MM, et al. Cell-based biological evaluation of a new bisamide FMS kinase inhibitor possessing pyrrolo[3,2-c]pyridine scaffold. Arch Pharm 2014;347:635–41.
  • El-Gamal MI, Jung M-H, Lee WS, et al. Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Eur J Med Chem 2011;46:3218–26.
  • Jung M-H, El-Gamal MI, Abdel-Maksoud MS, et al. Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2. Bioorg Med Chem Lett 2012;22:4362–7.
  • Khan MA, El-Gamal MI, Abdel-Maksoud MS, et al. Broad-spectrum antiproliferative activity of diarylureas and diarylamides possessing pyrrolo[3,2-c]pyridine scaffold. J Pharm Pharmacol 2014;2:157–69.
  • Gamal El-Din MM, El-Gamal MI, Abdel-Maksoud MS, et al. Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties. Eur J Med Chem 2016;119:122–31.
  • Wang X, Zhi B, Baum J, et al. A Practical Synthesis of 2-((1H-Pyrrolo[2,3-b]pyridine-4-yl)methylamino)-5-fluoronicotinic Acid. J Org Chem 2006;71:4021–3.
  • Girgis NS, Larson SB, Robins RK, et al. The synthesis of 5‐azaindoles by substitution‐rearrangement of 7‐azaindoles upon treatment with certain primary amines. J Heterocycl Chem 1989;26:317–25.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.